Literature DB >> 24008854

Carbapenem resistance in Acinetobacter baumannii: where is it heading?

Özcam Deveci1, Tuba Dal, Recep Tekin, Fatma Bozkurt, Alicem Tekin, Saim Dayan.   

Abstract

In the context of the substantial increase in antibiotic resistance rates of Acinetobacter baumannii, we aimed to evaluate the susceptibility rate changes of A. baumannii strains for carbapenems. A. baumannii strains isolated from patients diagnosed with healthcare-associated infections between 2007-2010 were included. A total of 127 A. baumannii strains [53 (42%) from the intensive care unit and 74 (58%) from the non-intensive care unit] were isolated. Conventional methods and an automated microbiology system were used for identification. Susceptibility testing was studied by Kirby-Bauer disk diffusion method. In 2007, five of 26 strains, in 2008, 18 of 31, in 2009, 10 of 35, in 2010, and 20 of 35 were obtained from intensive care unit patients. The susceptibility rate for imipenem was 50% in 2007 but 20% in 2010, while for meropenem it was 55% in 2007 but 12% in 2010. Prevention and control of antibiotic resistance among Acinetobacter species needs antibiotic usage restrictions and infection control precautions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24008854

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  2 in total

1.  Bacterial Epidemiology and Antimicrobial Resistance in the Surgery Wards of a Large Teaching Hospital in Southern Italy.

Authors:  Silvano Esposito; Renato Gioia; Giuseppe De Simone; Silvana Noviello; Domenico Lombardi; Vincenzo Giuseppe Di Crescenzo; Amelia Filippelli; Maria Rosaria Rega; Angelo Massari; Maria Giovanna Elberti; Lucilla Grisi; Giovanni Boccia; Francesco De Caro; Sebastiano Leone
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-06-01       Impact factor: 2.576

2.  Comparative Antimicrobial Activity of Hp404 Peptide and Its Analogs against Acinetobacter baumannii.

Authors:  Min Ji Hong; Min Kyung Kim; Yoonkyung Park
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.